Plus Therapeutics is pleased to announce the initiation of the ReSPECT-LM dose optimization clinical trial for REYOBIQ™ (rhenium Re 186 obisbemeda), a radiotherapeutic designed to target and treat leptomeningeal metastases (LM)—a devastating complication of metastatic cancer with limited treatment options.
The primary objective of this newly launched Phase 1/2 trial is to determine the optimal dosing schedule for use in a future registrational trial. It builds upon the recommended Phase 2 dose identified in the successfully completed first-in-human Phase 1 portion of the single-dose ReSPECT-LM study.
This important trial milestone is further enabled by a $17.6 million funding award from the Cancer Prevention and Research Institute of Texas (CPRIT)—underscoring both the urgency and promise of this targeted therapeutic approach for patients with LM stemming from cancers such as breast cancer, lung cancer, and other solid tumors.
“Initiating the dose optimization phase marks another step forward in our commitment to bringing precision radiotherapeutics to patients suffering from leptomeningeal metastases,” said Dr. Marc Hedrick, President & CEO of Plus Therapeutics.
Read the full press release: View Press Release
Learn more about the ReSPECT-LM clinical trial, including study goals, design, and eligibility information:
respect-trials.com/lm
#PlusTherapeutics #PSTV #ReSPECTLM #REYOBIQ #LeptomeningealMetastases #MetastaticCancer #CancerResearch #ClinicalTrials #BreastCancer #LungCancer #BrainCancer #Radiotherapeutics #OncologyInnovation #CPRIT
Recent Comments